Saturday 17 October 2026 Export GHRS’s income statement to Excel — free account

GH Research PLC

In the quarter to June 2026, EPS fell 53.3%, free cash flow fell 66.6% and total debt fell 97.9%, each against the same quarter a year earlier.

18.16 0.65 −3.46%

Follow GHRS

Alert me

Market cap: $1.3B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 23.48%

Capital & Financial Ratios $m

Market Cap 1,290.00

Revenue —

Net Income (62.27)

Free Cash Flow (51.84)

Net Debt (362.64)

Current Ratio 28.70

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.36

Past 5Y EPS Growth —

This Y EPS Growth (51.26%)

Next Y EPS Growth (53.19%)

Next Y revenue growth —

Next 5Y EPS Growth (28.78%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 79.39%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	162	149	281	363
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	5	5	6
	164	154	286	369

	2023	2024	2025	Q'26
Payables	3	4	4	6
ST’ Debt	—	—	—	—
Other	3	5	4	7
	7	9	8	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	118.11%	3.84%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(15)	—	—	—
’25	(9)	(9)	(14)	(12)	(44)
’24	(10)	(10)	(12)	(10)	(42)
’23	(7)	(8)	(10)	(8)	(33)
’22	(6)	(5)	(8)	(7)	(26)
’21	(1)	(1)	(9)	(4)	(15)
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(15)	—	—	—
’25	(9)	(9)	(14)	(12)	(44)
’24	(10)	(10)	(12)	(10)	(42)
’23	(7)	(8)	(10)	(8)	(33)
’22	(6)	(5)	(8)	(7)	(26)
’21	(1)	(1)	(9)	(4)	(15)
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.31)	(0.23)	—	—	—
’25	(0.19)	(0.15)	(0.23)	(0.23)	(0.79)
’24	(0.15)	(0.20)	(0.23)	(0.17)	(0.75)
’23	(0.21)	(0.15)	(0.11)	(0.21)	(0.68)
’22	(0.11)	0.01	(0.01)	(0.32)	(0.43)
’21	(0.04)	(0.05)	(0.04)	(0.09)	(0.21)
’20	0.00	0.00	0.00	(0.01)	(0.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	12.38	8.46	5.05	5.12	7.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	30.43	24.25	14.64	14.99	20.50
People
People	Employees	—	—	—	—	8	14	32	49	50	73
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	0.00	0.00	—	—	—
	EBT	—	—	—	0	0	(9)	(22)	(36)	(39)	(48)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	0	0	(9)	(22)	(36)	(39)	(48)
	Depreciation	—	—	—	—	—	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	0.00	(0.02)	(0.21)	(0.43)	(0.68)	(0.75)	(0.79)
	Cash flow	—	—	—	0.00	(0.01)	(0.35)	(0.50)	(0.64)	(0.81)	(0.71)
	Capex	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	0.00	(0.01)	(0.35)	(0.50)	(0.64)	(0.81)	(0.72)
	Book value	—	—	—	0.01	0.20	6.35	4.80	4.21	3.44	4.58
	Shares, m	—	—	—	70	28	44	52	52	52	61
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	0	0	(15)	(26)	(33)	(42)	(44)
	Capex	—	—	—	—	—	0	0	0	0	0
	Free cash flow	—	—	—	0	0	(15)	(26)	(33)	(42)	(44)
Balance, $m
Balance, $m	Working capital	—	—	—	0	6	277	164	157	145	278
	Total debt	—	—	—	—	—	—	—	1	0	0
	Net debt	—	—	—	0	(6)	(277)	(166)	(161)	(149)	(281)
	Shareholders’ equity	—	—	—	0	6	277	250	219	179	280
Returns, %
Returns, %	ROA	—	—	—	(123.02)	(13.90)	(6.44)	(8.41)	(14.81)	(18.80)	(20.26)
	ROIC	—	—	—	0.00	0.00	(2,365.29)	(22.77)	(44.39)	(104.83)	0.00
	ROE	—	—	—	(10.34)	(14.70)	(6.51)	(8.52)	(15.18)	(19.58)	(21.04)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OMER Omeros Corporation	$1.4B	9.5×	2.1×	+35.46% (above 0%: growing)	n/m	+118.70% (above 0%: growing)	97.20%	0.26%	Compare
INBX Inhibrx Biosciences, Inc.	$1.3B	— (loss-making)	— (loss-making)	+992.44% (above 0%: growing)	n/m	+0.12% (above 0%: growing)	100.00%	0.00%	Compare
ORIC Oric Pharmaceuticals, Inc.	$1.3B	— (loss-making)	—	—	n/m	−3.42% (below 0%: shrinking)	0.00%	0.00%	Compare
TYRA Tyra Biosciences, Inc.	$1.3B	— (loss-making)	—	—	n/m	−31.34% (below 0%: shrinking)	0.00%	0.00%	Compare
GHRS GH Research PLC	$1.3B	— (loss-making)	—	—	n/m	−66.62% (below 0%: shrinking)	0.00%	0.00%
NKTR Nektar Therapeutics	$1.3B	— (loss-making)	— (loss-making)	−9.34% (below 0%: shrinking)	n/m	−65.73% (below 0%: shrinking)	100.00%	(417.94%)	Compare
DRTS Alpha Tau Medical Ltd.	$1.2B	— (loss-making)	—	—	n/m	−30.42% (below 0%: shrinking)	0.00%	0.00%	Compare
SNDX Syndax Pharmaceuticals, Inc.	$1.2B	— (loss-making)	— (loss-making)	+91.76% (above 0%: growing)	n/m	+65.47% (above 0%: growing)	95.59%	(54.95%)	Compare
TSHA Taysha Gene Therapies, Inc.	$1.2B	— (loss-making)	— (loss-making)	+206.77% (above 0%: growing)	n/m	−100.28% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.3B	—	—	+91.76%	—	−16.92%	96.40%	0.00%

All 614 Biotechnology stocks →

GH Research PLC (GHRS) key facts

GH Research PLC (GHRS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, GHRS traded at $18.16, a market capitalization of $1.3 billion.
Return on equity was −21.0% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.